Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Targeting the PI3K pathway in patients who fail JAK inhibitor therapy

Aaron Gerds • 24 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms Ruxolitinib

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the promise of targeting the PI3K pathway in patients who fail JAK inhibitor therapy, and the potential long-term benefits of this therapeutic strategy. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

More from Aaron Gerds

1:27
Real-world use of fedratinib in patients with MF who have failed on ruxolitinib
Aaron Gerds • 6 Dec 2023
1:56
Treating elderly, non-transplant eligible patients with MF
Aaron Gerds • 6 Dec 2023
2:39
The MOST study: differences in disease progression amongst patients with low-risk MF
Aaron Gerds • 6 Dec 2023
1:30
XPORT-MF-044 trial: evaluating selinexor in JAK inhibitor-naïve MF and moderate thrombocytopenia
Aaron Gerds • 6 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals